噻氯吡啶联合低分子肝素治疗急性脑梗死的临床研究

摘要

目的 观察噻氯吡啶联合低分子肝素治疗急性脑梗死的临床效果.方法 将100例急性脑梗死患者随机均分为两组,治疗组50例给予噻氯吡啶,每天2次,每次250 mg,同时皮下注射低分子肝素80 IU/kg,每天2次,间隔12小时;对照组50例仅给予噻氯吡啶,每天2次,每次250mg.14天1个疗程,治疗组和对照组的其他治疗均相同.治疗前后对患者的神经功能(ESS)和日常生活活动能力指数(Bathel指数)进行评定,同时检测并记录患者血液流动学指标的变化.结果 治疗组ESS评分及日常生活活动能力指数变化都比对照组大,差异有统计学意义(P＜0.01);两组治疗后血液中血小板、纤维蛋白原和血浆黏度的差异均有统计学意义(P＜0.01).结论 噻氯吡啶联合低分子肝素治疗急性脑梗死能有效控制病情的发展,使临床疗效得到提高,应大力推广.%Objective To study the clinical effect of Ticlopidine combined with low molecular weight heparin (LMWH) in the treatment of acute cerebral infarction (ACI).Methods 100 cases of ACI were randomly divided into two groups.50 patients in treatment group were given Ticlopidine (250 mg,twice a day) and LMWH (80 IU/kg,twice a day); while 50 patients in control group were given only Ticlopidine (250 mg,twice a day),2 weeks as a course of treatment.Evaluated the change of patients' ESS grade,Bathel index and hemorheology after treatment.Result There were statistically significant difference in the change of ESS grade,Bathel index and hemorheology between two groups (P ＜ 0.01).Conclusion The clinical effect of Ticlopidine combined with low molecular weight heparin in the treatment of ACI is obviously,which can control the progression of disease and should be popularized in clinic.